470 related articles for article (PubMed ID: 2493023)
1. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
2. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
Cordido F; Peñalva A; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
[TBL] [Abstract][Full Text] [Related]
3. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
[TBL] [Abstract][Full Text] [Related]
4. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
Cordido F; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
[TBL] [Abstract][Full Text] [Related]
5. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
[TBL] [Abstract][Full Text] [Related]
6. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
[TBL] [Abstract][Full Text] [Related]
7. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
Peñalva A; Muruais C; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
[TBL] [Abstract][Full Text] [Related]
8. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
[TBL] [Abstract][Full Text] [Related]
9. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
10. Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men.
Coiro V; Volpi R; Bertoni P; Finzi G; Marcato A; Caiazza A; Colla R; Giacalone G; Rossi G; Chiodera P
Gerontology; 1992; 38(4):217-22. PubMed ID: 1358762
[TBL] [Abstract][Full Text] [Related]
11. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
Ismail IS; Scanlon MF; Peters JR
Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
[TBL] [Abstract][Full Text] [Related]
12. Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.
Castro RC; Vieira JG; Chacra AR; Besser GM; Grossman AB; Lengyel AM
Acta Endocrinol (Copenh); 1990 Mar; 122(3):385-90. PubMed ID: 2109445
[TBL] [Abstract][Full Text] [Related]
13. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
[TBL] [Abstract][Full Text] [Related]
14. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
15. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
Ghigo E; Goffi S; Arvat E; Nicolosi M; Procopio M; Bellone J; Imperiale E; Mazza E; Baracchi G; Camanni F
Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
[TBL] [Abstract][Full Text] [Related]
16. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
[TBL] [Abstract][Full Text] [Related]
17. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
[TBL] [Abstract][Full Text] [Related]
18. Sexual dimorphism of pyridostigmine potentiation of growth hormone (GH)-releasing hormone-induced GH release in humans.
Barbarino A; Corsello SM; Tofani A; Sciuto R; Della Casa S; Rota CA; Barini A
J Clin Endocrinol Metab; 1991 Jul; 73(1):75-8. PubMed ID: 2045474
[TBL] [Abstract][Full Text] [Related]
19. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.
Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB
J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535
[TBL] [Abstract][Full Text] [Related]
20. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
